{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:35:12Z","timestamp":1777419312369,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2008,4]]},"abstract":"\n OBJECTIVE:<\/jats:title>\n To examine the evidence regarding the impact of carvedilol on the serum lipid profile.<\/jats:p>\n <\/jats:sec>\n \n DATA SOURCES:<\/jats:title>\n Searches in MEDLINE and International Pharmaceutical Abstracts (1966\u2013December 2007) were conducted. Search terms included carvedilol, cholesterol, lipids, hyperlipidemia, and \u03b2-blockers.<\/jats:p>\n <\/jats:sec>\n \n STUDY SELECTION AND DATA EXTRACTION:<\/jats:title>\n Published studies and case reports that evaluated the impact of carvedilol on the lipid profile were reviewed. One study was excluded because it evaluated carvedilol for an off-label use and was a small Phase 2 pilot study that evaluated the results of only 10 patients.<\/jats:p>\n <\/jats:sec>\n \n DATA SYNTHESIS:<\/jats:title>\n \n Twelve studies were available for review; 6 of these compared carvedilol with \u03b2\n 1<\/jats:sub>\n -selective antagonists. Three studies compared carvedilol with other antihypertensive medications; 2 of those studies evaluated total cholesterol only. Carvedilol alone was evaluated for its effects on lipids in 3 small single-group studies. In 4 of the 12 studies, carvedilol independently improved the lipid profile significantly, while the drug had a nonsignificant, neutral effect on the lipid profile in 3 studies. Furthermore, in 4 of the 12 studies, carvedilol was compared with other antihypertensive medications. In 3 of these 4 studies, the other drugs worsened the lipid profile significantly compared with carvedilol, while carvedilol significantly improved the lipid profile in the other study. Finally, carvedilol had a potentially negative effect on high-density lipoprotein cholesterol in a single-group study, but p values were not reported.\n <\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS:<\/jats:title>\n \n It is clear that \u03b2\n 1<\/jats:sub>\n -selective antagonists worsen the lipid profile compared with carvedilol. However, it is unclear whether carvedilol independently makes an improvement or has a neutral effect on the lipid profile. Carvedilol should be an important treatment consideration in patients with heart failure and\/or hypertension with dyslipidemia. However, many questions remain regarding this issue.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1345\/aph.1k447","type":"journal-article","created":{"date-parts":[[2008,3,25]],"date-time":"2008-03-25T20:34:30Z","timestamp":1206477270000},"page":"564-571","source":"Crossref","is-referenced-by-count":8,"title":["Impact of Carvedilol on the Serum Lipid Profile"],"prefix":"10.1177","volume":"42","author":[{"given":"Randall P","family":"Sharp","sequence":"first","affiliation":[{"name":"Randall P Sharp PharmD, Associate Professor of Pharmacy Practice, College of Pharmacy, Southwestern Oklahoma State University, Weatherford, OK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riaz","family":"Sirajuddin","sequence":"additional","affiliation":[{"name":"Riaz Sirajuddin MD, Cardiologist, Heart Solutions of Oklahoma, Oklahoma City, OK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imran M","family":"Sharief","sequence":"additional","affiliation":[{"name":"Imran M Sharief MD, Research Associate, Heart Solutions of Oklahoma"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2008,4,1]]},"reference":[{"key":"bibr1-aph.1K447","volume-title":"Package insert. Coreg (carvedilol)","year":"2007"},{"key":"bibr2-aph.1K447","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13800-7"},{"key":"bibr3-aph.1K447","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04560-8"},{"key":"bibr4-aph.1K447","unstructured":"National Institutes of Health, National Heart, Lung, and Blood Institute. JNC-7 express: the seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Publication no. 03-5223. Bethesda, MD: National Institutes of Health, December 2003."},{"key":"bibr5-aph.1K447","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2005.04679.x"},{"key":"bibr6-aph.1K447","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199118041-00010"},{"key":"bibr7-aph.1K447","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.47.421"},{"key":"bibr8-aph.1K447","first-page":"909","volume":"5","author":"Maqueda IG","year":"1994","journal-title":"Coron Artery Dis"},{"key":"bibr9-aph.1K447","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0012.1999.130608.x"},{"key":"bibr10-aph.1K447","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.18.2227"},{"key":"bibr11-aph.1K447","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2007.01.019"},{"key":"bibr12-aph.1K447","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/13.suppl_G.61"},{"key":"bibr13-aph.1K447","first-page":"23","volume":"91","author":"Ames R","year":"1998","journal-title":"Arch Mal Coeur"},{"key":"bibr14-aph.1K447","volume-title":"Package insert. Toprol XL (metoprolol succinate)","year":"2007"},{"key":"bibr15-aph.1K447","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-12-199706150-00004"},{"key":"bibr16-aph.1K447","first-page":"212","volume":"12","author":"Marchi F","year":"1995","journal-title":"Adv Ther"},{"key":"bibr17-aph.1K447","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199118041-00011"},{"key":"bibr18-aph.1K447","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2006.05504.x"},{"key":"bibr19-aph.1K447","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315487"},{"key":"bibr20-aph.1K447","doi-asserted-by":"publisher","DOI":"10.1007\/BF01409484"},{"key":"bibr21-aph.1K447","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050242"},{"key":"bibr22-aph.1K447","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.1967"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1K447","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1K447","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1K447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:10:19Z","timestamp":1777374619000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1K447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1345\/aph.1K447"],"URL":"https:\/\/doi.org\/10.1345\/aph.1k447","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}